GlycoMimetics Inc - Company Profile
Powered by
All the data and insights you need on GlycoMimetics Inc in one report.
- Save hours of research time and resources with
our up-to-date GlycoMimetics Inc Strategy Report
- Understand GlycoMimetics Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
GlycoMimetics Insights
Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.
A sample of GlycoMimetics Insights data
Headline | Published | Journalists |
---|---|---|
Deserunt mollit sunt Lorem laborum do id aliqua dolore | 20 Nov 2019 | Lorem |
GlycoMimetics’ Phase III uproleselan trial in relapsed/refractory AML protocol under review to allow patients who have failed on AbbVie/Roche’s Venclexta, sources say | 14 Nov 2019 | Ayisha Sharma |
GlycoMimetics/Pfizer's rivipansel Phase III trial in SCD may face challenges to reach statistical significance in reducing VOC recovery time due to duration variability, experts say | 11 Feb 2019 | Mariana Lenharo |
GlycoMimetics’ planned AML Phase III GMI-1271 program would need large sample size, but adaptive design could ease way forward – experts | 25 Jan 2017 | Alaric DeArment |
Feature
Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.
Benefit
Drug Insights:
- Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
- Material intelligence on competitors, including breaking news
- Insight on companies’ business development needs and strategies
Outsourcing Insights:
Insight on companies’ CRO and business development needs, strategies and relationships
Value
Remove risk and uncertainty
Gain a competitive edge
Secure actionable leads
Premium databases is part of our industry range of products
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer